Sodium Picosulfate |
Catalog No.GC16452
One-Click Copy Product Info
|
laxative
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 10040-45-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sodium Picosulfate is a laxative.
Sodium Picosulfate is a laxative that inhibits water and electrolytes absorption and increases their secretion. In cultured human, rat and rabbit liver cells, sodium picosulfate (1600 μg/ml) reduced the protein content in rabbit liver cells. Also, hepatocytes of rabbit were more sensitive to sodium picosulfate [1].
In patients underwent a barium enema, sodium picosulphate reduced the serum concentrations of sodium, potassium and urea by 1.299, 0.163 and 0.556, respectively [2]. In patients with morphine sulphate induced constipation, sodium picosulfate was well-tolerated and significantly improved constipation with normal stool consistency, not requiring suppositories, manual evacuation or enemas [3]. In patients with chronic constipation, sodium picosulphate (7 mg) improved stool frequency and straining in 82.8% patients and reduced bloating [4].
References:
[1]. Nishikawa J, Kast A. Effects of sodium picosulfate, bisacodyl and sennoside in cultured human, rat and rabbit liver cells. Arzneimittelforschung, 1981, 31(6): 1010-1013.
[2]. Ryan F, Anobile T, Scutt D, et al. Effects of oral sodium picosulphate Picolax on urea and electrolytes. Nurs Stand, 2005, 19(45): 41-45.
[3]. Twycross RG, McNamara P, Schuijt C, et al. Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. Palliat Med, 2006, 20(4): 419-423.
[4]. Wulkow R, Vix JM, Schuijt C, et al. Randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of the acute use of sodium picosulphate in patients with chronic constipation. Int J Clin Pract, 2007, 61(6): 944-950.
| Cas No. | 10040-45-6 | SDF | |
| Chemical Name | disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate | ||
| Canonical SMILES | C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+] | ||
| Formula | C18H15NO8S2.2Na | M.Wt | 481.41 |
| Solubility | ≥ 13.05mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0772 mL | 10.3862 mL | 20.7723 mL |
| 5 mM | 415.4 μL | 2.0772 mL | 4.1545 mL |
| 10 mM | 207.7 μL | 1.0386 mL | 2.0772 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)